Plx-200 (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
19 | ライソゾーム病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04637282 (ClinicalTrials.gov) | February 1, 2021 | 4/11/2020 | Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 | A Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease | Juvenile Neuronal Ceroid Lipofuscinosis | Drug: PLX-200 | Polaryx Therapeutics, Inc. | NULL | Not yet recruiting | 5 Years | 18 Years | All | 24 | Phase 2 | NULL |